First Opinion By Gillian Woollett The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means
Pharmalot By Ed Silverman FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?
Pharmalot By Ed Silverman AbbVie accuses a company of recruiting an employee in order to steal Humira secrets
Pharmalot By Ed Silverman Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs
Business By Matthew Herper Merck to spin off new $6.5 billion firm focused on women’s health, older drugs
First Opinion By Howard S. Hochster FDA’s naming rule for biosimilars has undermined Congress and health care
Health By Michelle Andrews — Kaiser Health News Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch
Pharmalot By Ed Silverman FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug
Pharmalot By Ed Silverman Once again, the viability of the U.S. biosimilar market is thrown into question
Pharmalot By Ed Silverman In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition
Pharmalot By Ed Silverman What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years
Pharmalot By Ed Silverman Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks
Pharmalot By Ed Silverman Biosimilars got the cold shoulder from health plans when it came to preferred coverage
Pharmalot By Ed Silverman Large employers could have saved money if more biosimilars had been prescribed
Pharmalot By Ed Silverman Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins
Pharmalot By Ed Silverman FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake
Politics By Lev Facher Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation
Pharmalot By Ed Silverman Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals
Pharmalot By Ed Silverman Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast
First Opinion By Jessica Sagers and Peter Kolchinsky Booker-Sanders-Harris drug affordability bureau could be brilliant
Pharmalot By Ed Silverman Pharmalittle: Judge summons opioid CEOs before trial starts; Republicans fail to change Pelosi drug pricing bill
First Opinion By Jonathan Kimball Trade agreement drug monopoly is obsolete given faster, better drug discovery
Pharmalot By Ed Silverman Pharmalittle: New records show drug makers’ opioid push; Senate bill would cap Medicare drug price hikes
Pharmalot By Ed Silverman Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin
Pharmalot By Ed Silverman Pharmalittle: Democrats eye negotiating for all drug plans; feds want part of Oklahoma settlement with Purdue